Patents Examined by Shirley V. Gembeh
  • Patent number: 10189845
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 29, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
  • Patent number: 10188746
    Abstract: A conjugate of formula (A): Wherein Y is selected from formulae A1 and A2: Z1 is a C1-3 alkylene group; Z2 is a C1-3 alkylene group; Q is: where QX is such that Q is an amino-acid residue, a dipeptide residue or a tripeptide residue; L is a linker connected to a cell binding agent; CBA is the cell binding agent; and n is an integer between 0 and 48.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: January 29, 2019
    Inventor: Philip Wilson Howard
  • Patent number: 10189827
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 29, 2019
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • Patent number: 10172942
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: January 8, 2019
    Assignee: Pfizer Inc.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • Patent number: 10172844
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 8, 2019
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • Patent number: 10159653
    Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde but otherwise identical. The composition comprising cinnamaldehyde can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In an embodiment, the composition comprising cinnamaldehyde is administered to a human. The composition comprising cinnamaldehyde may be a medicament, a food product or a supplement to a food product.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: December 25, 2018
    Assignee: Nestec S.A.
    Inventors: Stephanie Michlig Gonzalez, Johannes Le Coutre
  • Patent number: 10155006
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: December 18, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 10154950
    Abstract: The invention pertains to an antimicrobial disinfecting composition including: a) 0.1-1 wt. % of each of at least one food allowed organic acid or a salt thereof; b) 0.1-1 wt. % of each of at least one amine oxide amphoteric surfactant, the composition having a total surfactant content which does not exceed 8 wt. %, wherein the total amount of betaine amphoteric surfactants in the composition is in the range of 0-75 wt. % of the total amount of amine oxide amphoteric surfactant. The composition is particularly suitable for use on skin or mucous membranes. On the one hand it shows good disinfecting properties, but on the other hand it does not lead to any use precautions or hazard or warning statements on the product label.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 18, 2018
    Assignee: HYGIENIX BV
    Inventor: Ilja Bobbert
  • Patent number: 10155002
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: December 18, 2018
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, Richard Chesworth, Kenneth William Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah Kathleen Knutson, Timothy James Nelson Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Patent number: 10143699
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 4, 2018
    Assignee: Calithera Biosciences, Inc.
    Inventors: Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
  • Patent number: 10143697
    Abstract: A pharmaceutical composition comprises a HDAC inhibitor, a pharmaceutically acceptable acid or a salt thereof or a mixture thereof and a steroid or a pharmaceutically acceptable salt thereof as well use of said pharmaceutical composition for the treatment of cancer as a pretreatment prior to other treatments. Said HDAC inhibitor or steroid may alternatively be administrated separately prior to additional treatments.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 4, 2018
    Assignee: VALCURIA AB
    Inventors: Kristina Drott, Thomas Relander
  • Patent number: 10138441
    Abstract: The present invention relates to a composition having improved or enhanced fidelity and/or longevity of the fragrance profile, comprising fragrance materials in a diamond construction and at least one substantially non-odorous fragrance modulator. The invention also relates to methods of use of the compositions for perfuming suitable substrates, including hard surfaces and body parts, particularly skin and hair.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: November 27, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Lynette Anne Makins Holland, Christelle Marie Sandrine Bonnet, Fabienne Pastor, Jose Maria Velazquez Mendoza, Jonathan Richard Stonehouse, William Eoghan Staite, David Thomas Stanton, Oreste Todini, Stephen Robert Schofield, Sarah Kyakyo Kanyunyuzi Nyakana, Susana Fernandez Prieto, Johan Smets, Jeffrey John Scheibel, Isabelle Guimet
  • Patent number: 10137070
    Abstract: Provided herein are a cosmetic composition, a health functional food composition, a pharmaceutical composition, and a quasi-drug composition that include ionone or a salt thereof as an active ingredient and have an effect of enhancing skin moisturizing, exfoliating skin, improving skin elasticity, inhibiting erythema, improving skin wrinkles, or alleviating skin photoaging.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: November 27, 2018
    Inventor: Tae Sun Park
  • Patent number: 10137099
    Abstract: The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: November 27, 2018
    Inventor: Alan B Cash
  • Patent number: 10130606
    Abstract: Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: November 20, 2018
    Inventor: Ronald Erwin Boch
  • Patent number: 10123970
    Abstract: The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and a process of preparing it.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: November 13, 2018
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Sanjay Kumar Motwani, Shashikanth P. Isloor, Vinod Arora
  • Patent number: 10124001
    Abstract: Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-?) for inhibiting the growth of PKC-?-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: November 13, 2018
    Assignee: University of Canberra
    Inventors: Sudha Rao, Anjum Zafar
  • Patent number: 10117849
    Abstract: The present disclosure provides a water dispersible granule formulation comprising from about 5% to about 80% (w/w) of monensin; from about 1% to about 20% (w/w) of one or more surfactants; from about 1% to about 30% (w/w) of one or more binders; from about 1% to about 90% (w/w) of one or more fillers; and water up to about 2% (w/w). The present disclosure also provides a process for the preparation of a water dispersible monensin granule formulation. The present disclosure further provides a method of administering a therapeutically effective amount of a water dispersible monensin granule formulation to an animal.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 6, 2018
    Assignee: Elanco US, Inc.
    Inventors: Kim Ewing Melville Agnew, Constantine Paul Benikos, William Austin Hewitt, Edward John Key, John Malcolm Lloyd
  • Patent number: 10119168
    Abstract: The technology described herein is directed to the diagnosis, prognosis, and treatment of kidney fibrosis, e.g., chronic kidney disease.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: November 6, 2018
    Inventors: Vishal S. Vaidya, Florin Craciun, Amrendra K. Ajay
  • Patent number: 10111952
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: October 30, 2018
    Assignee: MERCK PATENT GmbH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig